<< Read Full Article
<< Read Full Article
Review Date Is Big News for CV Therapeutics
Updated from 2:28 p.m. EDT
CV Therapeutics(CVTX Quote) was the biggest gainer on the Nasdaq Thursday after the FDA scheduled an advisory group hearing on its angina candidate Ranexa.
The shares surged $6.20, or 34%, to $24.42 on about four times their normal volume after the FDA's Cardiovascular and Renal Drugs Advisory Committee scheduled the review for Dec. 9, 2003. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,452.00 | 1,107.93 | 2,201.05 | 36.03 |
Oil *
72.08
|
|
DOWN
49.05
|
DOWN
6.18
|
DOWN
11.05
|
UP
0.57
|
10 Yr
3.60%
SPDR Gold
110.21
|
|
-0.47%
|
-0.55%
|
-0.50%
|
+1.61%
|
Data delayed 20 minutes |
Connect with TheStreet